Paradigm Capital Management Inc. NY Purchases New Position in CONMED Corporation $CNMD

Key Points

• Paradigm Capital Management purchased 538,245 shares of CONMED in the second quarter, valued at approximately $17.6 million and representing about 1.8% of the company.
• CONMED exceeded quarterly expectations, reporting $1.38 in earnings per share versus the $1.11 consensus estimate and revenue of $343.5 million, while issuing fiscal 2026 EPS guidance of $4.48–$4.60.
• Despite the earnings beat and recent share gains, Wall Street remains cautious: the stock carries an average “Reduce” rating and a consensus price target of $41.40, below its reported $51.52 price.

Paradigm Capital Management Inc. NY purchased a new stake in shares of CONMED Corporation (NYSE:CNMD - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 538,245 shares of the company's stock, valued at approximately $17,617,000. Paradigm Capital Management Inc. NY owned about 1.80% of CONMED as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its holdings in shares of CONMED by 19.9% in the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company's stock valued at $857,000 after purchasing an additional 2,357 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of CONMED by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company's stock valued at $1,108,000 after buying an additional 800 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in CONMED by 5.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company's stock worth $4,993,000 after buying an additional 4,565 shares in the last quarter. Intech Investment Management LLC grew its holdings in CONMED by 34.6% during the first quarter. Intech Investment Management LLC now owns 22,505 shares of the company's stock worth $1,359,000 after buying an additional 5,780 shares in the last quarter. Finally, Creative Planning purchased a new stake in CONMED in the 2nd quarter valued at $310,000.

CONMED Stock Up 0.9%

CNMD opened at $51.52 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 1.48 and a debt-to-equity ratio of 0.63. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of 27.85, a PEG ratio of 2.33 and a beta of 0.88. CONMED Corporation has a twelve month low of $31.44 and a twelve month high of $56.63. The company's 50-day moving average price is $42.06 and its two-hundred day moving average price is $39.54.

CONMED (NYSE:CNMD - Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.27. CONMED had a net margin of 4.12% and a return on equity of 14.31%. The firm had revenue of $343.49 million during the quarter, compared to the consensus estimate of $337.60 million. During the same period in the prior year, the firm earned $1.15 EPS. The company's revenue was up .3% compared to the same quarter last year. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. As a group, equities analysts expect that CONMED Corporation will post 4.54 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Zacks Research upgraded CONMED from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of CONMED from a "hold" rating to a "buy" rating in a report on Monday, July 20th. BMO Capital Markets started coverage on shares of CONMED in a research report on Wednesday, July 8th. They set a "market perform" rating and a $36.00 price target on the stock. Piper Sandler restated a "neutral" rating and set a $45.00 price target (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. Finally, Bank of America reaffirmed an "underperform" rating and issued a $40.00 price objective on shares of CONMED in a research report on Monday, June 29th. Six research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Reduce" and a consensus price target of $41.40.

About CONMED

CONMED Corporation NYSE: CNMD is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company's product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Corporation (NYSE:CNMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source